Inventor · disambiguated record
Volker Germaschewski
Also filed as: GERMASCHEWSKI VOLKER
27 granted patents·20 pending applications·317 citations·filing 2003–2024
96Inventor score
Files withKYMAB LTD24GLAXO GROUP LTD10BURBIDGE STEPHEN ANTHONY3ELLIS JONATHAN HENRY3CLEGG STEPHANIE JANE2
Top patents by PatentIndex Score
47 records- 0197US9617338B1Antibodies and immunocytokinesKYMAB LTD·Filed 2016·Granted Apr 11, 2017·78 cites·20 claims
- 0297US9567399B1Antibodies and immunocytokinesKYMAB LTD·Filed 2016·Granted Feb 14, 2017·96 cites·21 claims
- 0396US10604576B2Antibodies and immunocytokinesKYMAB LTD·Filed 2017·Granted Mar 31, 2020·25 cites·14 claims
- 0496US9957323B2Anti-ICOS antibodiesKYMAB LTD·Filed 2017·Granted May 1, 2018·27 cites·26 claims
- 0591US10667501B2Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulinsKYMAB LTD·Filed 2014·Granted Jun 2, 2020·15 cites·6 claims
- 0689US10703814B2Method of treatment with humanized anti-IL-18 antibodiesGLAXO GROUP LTD·Filed 2018·Granted Jul 7, 2020·2 cites·13 claims
- 0788US12209128B2Anti-PD-L1 antibodiesKYMAB LTD·Filed 2021·Granted Jan 28, 2025·1 cites·6 claims
- 0888US11965026B2Anti-PD-L1 and IL-2 cytokinesKYMAB LTD·Filed 2017·Granted Apr 23, 2024·3 cites·19 claims
- 0986US7612183B2Humanised anti-mag antibody or functional fragment thereofGLAXO GROUP LTD·Filed 2003·Granted Nov 3, 2009·21 cites·15 claims
- 1085US11858996B2Anti-ICOS antibodiesKYMAB LTD·Filed 2017·Granted Jan 2, 2024·2 cites·29 claims
- 1185US8133978B2Humanised anti-interleukin-18 antibodyELLIS JONATHAN HENRY·Filed 2007·Granted Mar 13, 2012·7 cites·7 claims
- 1283US8362208B2ImmunoglobulinsGLAXO GROUP LTD·Filed 2006·Granted Jan 29, 2013·6 cites·2 claims
- 1383US2024360218A1Anti-pd-l1 and il-2 cytokinesKYMAB LTD·Filed 2024·Application pending·0 cites
- 1483US2024343810A1Multispecific antibodies for immuno-oncologyKYMAB LTD·Filed 2024·Application pending·0 cites
- 1581US8227576B2Antibodies against amyloid-β peptideBURBIDGE STEPHEN ANTHONY·Filed 2007·Granted Jul 24, 2012·7 cites·18 claims
- 1681US7858753B2ImmunoglobulinsGLAXO GROUP LTD·Filed 2005·Granted Dec 28, 2010·7 cites·23 claims
- 1781US2024158502A1Anti-icos antibodiesKYMAB LTD·Filed 2023·Application pending·0 cites
- 1877US10221234B2Antigen binding proteinsGLAXO GROUP LTD·Filed 2016·Granted Mar 5, 2019·2 cites·12 claims
- 1977US8858943B2Antigen binding proteinsBURBIDGE STEPHEN ANTHONY·Filed 2008·Granted Oct 14, 2014·6 cites·10 claims
- 2077US2022380467A1Anti-icos antibodiesKYMAB LTD·Filed 2022·Application pending·0 cites
- 2177US2022403029A1Anti-icos antibodiesKYMAB LTD·Filed 2022·Application pending·0 cites
- 2277US2023312720A1Multispecific antibodies for immuno-oncologyKYMAB LTD·Filed 2022·Application pending·0 cites
- 2375US11440960B2TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivoKYMAB LTD·Filed 2018·Granted Sep 13, 2022·1 cites·14 claims
- 2475US8637018B2Humanized anti-IL-18 antibodiesELLIS JONATHAN HENRY·Filed 2011·Granted Jan 28, 2014·2 cites·7 claims
- 2575US8071731B2Humanised anti-MAG antibody or functional fragment thereofELLIS JONATHAN HENRY·Filed 2008·Granted Dec 6, 2011·2 cites·6 claims
- 2671US8496932B2CompoundsCLEGG STEPHANIE JANE·Filed 2008·Granted Jul 30, 2013·3 cites·8 claims
- 2770US8921523B2Humanized anti-beta-amyloid antibodiesALARD PHILIPPE MARC LOUIS·Filed 2008·Granted Dec 30, 2014·4 cites·7 claims
- 2870US2023192847A1Tigit antibodies, encoding nucleic acids and methods of using said antibodies in vivoKYMAB LTD·Filed 2022·Application pending·0 cites
- 2964US9499617B2Humanized anti-IL-18 antibodiesGLAXO GROUP LTD·Filed 2013·Granted Nov 22, 2016·0 cites·7 claims
- 3063US2023233675A1Methods, regimens, combinations & antagonistsKYMAB LTD·Filed 2022·Application pending·0 cites
- 3161US2024199755A1Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the boneKYMAB LTD·Filed 2023·Application pending·0 cites
- 3258US2020267952A1Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulinsKYMAB LTD·Filed 2020·Application pending·0 cites
- 3357US2017029497A1ImmunoglobulinsGLAXO GROUP LTD·Filed 2016·Application pending·0 cites
- 3456US2020190191A1Multispecific antibody with combination therapy for immuno-oncologyKYMAB LTD·Filed 2017·Application pending·0 cites
- 3552US11648308B2Methods, regimens, combinations and antagonistsKYMAB LTD·Filed 2017·Granted May 16, 2023·0 cites·20 claims
- 3652US8828384B2CompoundsGLAXOSMITHKLINE·Filed 2013·Granted Sep 9, 2014·0 cites·4 claims
- 3750US9193784B2AntibodiesBURBIDGE STEPHEN ANTHONY·Filed 2012·Granted Nov 24, 2015·0 cites·16 claims
- 3849US2021214456A1Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the boneKYMAB LTD·Filed 2019·Application pending·0 cites
- 3948US2013287781A1ImmunoglobulinsGLAXO GROUP LTD·Filed 2013·Application pending·0 cites
- 4047US2025026813A1Antibodies against sars-cov-2 and uses thereofKYMAB LTD·Filed 2021·Application pending·0 cites
- 4145US2016024197A1Antibodies against amyloid-beta peptideGLAXO GROUP LTD·Filed 2015·Application pending·0 cites
- 4244US9434716B2Antigen binding proteinsBHINDER TEJINDER KAUR·Filed 2011·Granted Sep 6, 2016·0 cites·8 claims
- 4341US2011245470A1ImmunoglobulinsGLAXO GROUP LTD·Filed 2010·Application pending·0 cites
- 4436US2022073598A1AntagonistsKYMAB LTD·Filed 2019·Application pending·0 cites
- 4532US2012076787A1Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eyeADAMSON PETER·Filed 2010·Application pending·0 cites
- 4629US2012315267A1Novel usesCLEGG STEPHANIE JANE·Filed 2011·Application pending·0 cites
- 4724US8974782B2Treatment of stroke comprising anti-MAG antibodiesABILA BAMS·Filed 2012·Granted Mar 10, 2015·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Volker Germaschewski files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →